Le Lézard
Classified in: Health
Subject: SVY

Epilepsy -Epidemiology Forecast to 2025


NEW YORK, Nov. 17, 2017 /PRNewswire/ -- DelveInsight "Epilepsy  - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Epilepsy  in seven major markets (US, France, Germany, Italy, Spain, UK and Japan).

Read the full report: https://www.reportlinker.com/p05144678


It includes 10 years epidemiology historical and forecasted data of Epilepsy  prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Epilepsy . The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Scope of the Report
The Report includes the prevalent population and how will it change over the next eight years.
Prevalent or incident cases segmented by age and sex.
Coverage of key Epilepsy  subpopulations and its prevalent or incident cases
The key differences in epidemiology patterns across the seven market segments

Key Coverage and Benefits
The report will help in developing business strategies by understanding the trends shaping and driving the global Epilepsy  market.
Identifying prevalent patient populations as well as risk factors in the global Epilepsy  market will help to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Epilepsy  therapeutics in each of the markets covered.

Read the full report: https://www.reportlinker.com/p05144678

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 01:24
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...

at 01:17
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...



News published on and distributed by: